

7. BIBLIOGRAFIA

1. Medawar P. History of transplantation: Thirty-five recollections. Paul Terasaki. UCLA Tissue Typing. Los Angeles (USA) 1991.
2. Cooper DCK, Kemp E, Reemtsma, White DJG. Xenotrasplantation. Berlin, Heidelberg, Springer, 1991.
3. Starzl TE. Experience in hepatic transplantation. Filadelfia WB Saunders 1969; 408.
4. Starzl TE, Ishikawa M, Putnam CW et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to hyperacute rejection, and biliary duct reconstruction. Transplantation Proceedings 1974; 6:129
5. Gilnes GR, Boehmig HJ, Amemiya et al. Clinical heterotransplantation of the liver. Transplantation Proceedings 1970; 2: 506.
6. Calne RY. Organ transplantation between widely disparate species. Transplantation Proceedings 1970, 2:550-553
7. Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, Doyle H, Zeevi A, Warty V, Michaels M, Kusne S, Rudert WA, Trucco M. Baboon-to-human liver transplantation. The Lancet 1993; 341: 65-71
8. Starzl TE, Tzakis A Fung JJ, Todo S, Demetris AJ, Manez R, Marino IR, Valdivia L, Murase N. Prospects of clinical xenotransplantation. Transplantation Proceedings 1994; 26:1082-1088.
9. Heneine W, Tibell A, Switzer WM et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. TheLancet 1998; 358: 695-699.
10. Thiru S., Waldmann H. Pathology and immunology of transplantation and rejection. 2001 Ed. Blackell Science Ltd.
11. Arias M, Gómez-Fleitas M, De Francisco ALM. Xenotrasplnte. 1996 Ed. Sandoz Pharma SAE.
12. Platt JL, Turman MA, Noreen HJ, et al. 1990. An ELISA assay for xenoreactive natural antibodies. Trasplantation 1990; 49: 1000
13. Dalmaso A, Vercellotti GM, Fischel RJ, et al. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. American Journal of Pathology 1992, 140:1157
14. Platt JL, Fischel RJ, Matas AJ, et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991, 52:214-220
15. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogeneic endothelial cells. Transplantation 1991, 52:1037

7. Bibliografia

16. Platt JL, Vercellotti GM, Lindman BJ, et al. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. *Journal of Experimental Medicine* 1990, 171:1363-1368
17. Vanhove B, Bach FH. Human xenoreactive natural antibodies: avidity and targets on porcine endothelial cells. *Transplantation* 1993, 56:1251-1253
18. Turman MA, Casali P, Notkins AL, Bach FH, Platt JL. Polireactivity and antigen specificity of human xenoreactivity monoclonal and serum natural antibodies. *Transplantation* 1991; 52: 710-717.
19. Platt JL. The immunological barriers to xenotransplantation. *Critical Review of Immunology* 1996, 16:331-358
20. Collins BH, Parker W, Platt JL. Characterization of porcine endothelial cell determinants recognized by human natural antibodies. *Xenotransplantation* 1994; 1: 36-46.
21. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytotoxicity. *Nature Medicine* 1995, 1(12):1261-1267
22. Galili U, Shoberg S, Kobrin E, Stults C, Macjter B. Man, apes and old world monkeys differ from other mammals in the expression of α -galactosyl epitopes on nucleated cells. *Journal of Biological Chemistry* 1988; 263: 17755-17762.
23. Oriol RY, Koren E, Cooper DKC. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. *Transplantation* 1993, 56: 1433-1442.
24. Magnusson S, Mansson JE, Strokkan V, Jussila R, Kobayashi T, Rydberg L, Romano E, Breimer ME. Release of pig leukocytes during pig kidney perfusion and characterization of pig lymphocyte carbohydrate xenoantigens. *Xenotransplantation* 2003; 10: 432-445.
25. Wu GD, Cramer DV, Chapman FA, Oriol R, Makowka L. Genetic control of the humoral immune response to xenografts. I. Functional characterization of rat monoclonal antibodies to hamster heart xenografts. *Transplantation* 1995; 60: 1497-1503.
26. Dalmaso AP. The complement system in xenotransplantation. *Immunopharmacology* 1992, 24:149-160
27. Leventhal JR, Dalmaso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. *Transplantation* 1993, 55: 857-866
28. Miyagawa S, Shirakura R, Matsumiya G, et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT-175. *Transplantation* 1993, 55(4):709-713
29. Platt JL, Bach FH. The barrier to xenotransplantation. *Transplantation* 1991, 52: 937-947

30. Dalmaso AP, Platt JL. Prevention of complement activation of xenogeneic endothelial cells in an in vitro model xenograft hyperacute rejection by C1 inhibitor. *Transplantation* 1993, 56: 1171-1176.
31. Zhao Z, Termignon JL, Cardoso J et al. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination. *Transplantation* 1994; 57: 245-249.
32. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology the cardiac xenograft rejection in the guinea pig-to-rat model. *Transplantation* 1993; 56:1-8
33. Bach FH, Blackely ML, Van der Werf M et al. Discordant xenografting: a working model of problems and issues. *Xenotransplantation* 1993; 1: 8-16
34. Vercelloti GM, Platt JL, Bach FH, Dalmaso AP. Neutrophil adhesion to xenogeneic endothelium via iC3b. *Journal of Immunology* 1991, 146: 730-734
35. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. *Seminaries of Hematology* 1992, 29: 213.
36. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interaction. *Immunology Today* 1993, 14:500-505.
37. Dalmaso A. El complemento en el xenotrasplante de órganos. *Rev Clin Española* 1996, 196 (monográfico 1):50-58
38. Bach FH, Winkler H, Ferran C, et al. Delayed xenograft rejection. *Immunology Today* 1996, 17(8):379-384
39. Parker W, Saadi S, Lin SS, et al. Transplantation of discordant xenografts: a challenge revisited. *Immunology Today* 1996, 17:373-378
40. Saadi S, Holzkhecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. *Journal of Experimental Medicine* 1995, 182:1807-1814
41. Gerritsen ME, Bloor CM. Endothelial cell gene expression in response to injury. *FASEB Journal* 1993, 7:523-532
42. Saadi S, Ihrcke NS, Platt JL in *Principles of Immunomodulatory drug development in transplantation and autoimmunity* 1st edn (eds Lieberman R & Morris R) 31-35 (Raven, New York, 1996).
43. Platt JL et al. Transplantation of discordant xenografts: a review of progress. *Immunology Today* 1990; 11: 450-456.
44. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. *Transplantation* 1996, 62:303-310

7. Bibliografia

45. Sachs DH, Sablinski T. Tolerance across discordant xenogeneic barriers. *Xenotransplantation* 1995; 2: 234-239.
46. Bracy JL, Sachs DH, Iacomini J. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. *Science* 1998; 281: 1845-1847.
47. Onishi A et al. Pig cloning by microinjection of fetal fibroblast nuclei. *Science* 2000; 289: 1188-1190.
48. Polejaeva IA et al. Cloned piglets produced by nuclear transfer from adult somatic cells. *Nature* 2000; 407: 86-90.
49. Betthausen J et al. Production of cloned pigs from *in vitro* systems. *Nature Biotechnologies* 2000; 1055-1059.
50. Lin SS et al. The role of anti-Gal 1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. *Transplantation* 2000; 70: 1667-1674.
51. Lin Y, Vandeputte M, Waer M. Accommodation and T-independent B cell tolerance in rats with long term surviving hamster hearts xenografts. *Journal of Immunology* 1998; 160: 369-375.
52. Wrenshall LE, Cerra FB, Singh RK, Platt JL. Heparan sulphate initiates signals in murine macrophages leading to divergent biological outcomes. *Journal Immunology* 1995; 154: 871-880
53. Moses RD, Winn HJ, Auchincloss HJr. Multiple defects in cell surface molecule interactions across species are responsible for diminished xenogeneic T cell responses. *Transplantation* 1992; 53: 203-209.
54. Malyguine AM et al. Induction of procoagulant function in porcine endothelial cells by human NK cells. *Journal of Immunology* 1997; 159: 4659-4664.
55. Lin Y, Vandeputte M, Waer M. Natural killer cell and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. *Journal of Immunology* 1997; 158: 5658-5667.
56. Blakely ML, Van der Werf W, Berndt M, et al. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. *Transplantation* 1994, 58:1059-1066
57. Chong ASF, Shen J, Xiao F, et al. Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. *Transplantation* 1996, 62:90-96

58. Chong ASF, Li Ma L, Shen JK, et al. Modification of humoral responses by the combination of leflunomide and cyclosporine in Lewis rats transplanted with hamster hearts. *Transplantation* 1997, 64:1650-1657
59. Mollevi DG, Ribas Y, Ginesta MM, Serrano T, Mestre M, Vidal A, Figueras J, Jaurrieta E. Heart and liver xenotransplantation under low-dose tacrolimus: graft survival after withdrawal of immunosuppression. *Transplantation*, 2001; 71(2):217-23.
60. Platt JL, Vercellotti GM, Dalmaso AP, et al. Transplantation of discordant xenografts: a review of progress. *Immunology Today* 1990; 11: 450-456.
61. Bach FH, Turman MA, Vercelloti GM, Platt JL, Dalmaso AP. Accomodation: a working paradigm for progressig toward clinical discordant xenografting. *Trasplantation Proceedings* 1991; 23: 205-207.
62. Alexandre GPJ, Latinner D, Gianello P, et al. Preformed cytotoxic antibodies and ABO-incompatible grafts. *Clinical Transplantation* 1991, 5:583-587.
63. Cascalho M, Platt JL. Xenotrasplantation and other means of organ replacement. *Nature* 2001; 1: 154-160
64. Bach FH, Ferran C, Hechenleitner P, et al. Accomodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environement. *Nature Medicine* 1997, 3(2):196-204
65. Brouard S, Blancho G, Moreau A, et al. Long-term survival of hamster-to-rat cardiac xenografts in the absence of a Th2 shift. *Transplantation* 1998, 65:1555-1563
66. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. *Nature reviews. Immunology* 2003; 3:199-210.
67. Turka LA, Sayegh. T-Cell Tolerance. In Tilney NL, Strom TB, Paul LC. (Eds.) *Transplantation biology: Cellular and Molecular Aspects*. Lippincott-Raven Publishers, Philadelphia 1996.
68. Müller-Ruchholtz W. Concepts and Mechanisms of immune Activation, graft rejection, immunosupression, and tolerance. In Timmermann W, Gassel HJ, Ulrichs K, Zhong R, Thiede A (Eds.). *Organtransplantation in rats and mice*. Springer-Verlag Berlin Heidelberg 1998, Germany.
69. Bollinger RR. Immunological aspects of liver transplantation. In Morris P, Tilney N, eds. *Transplantation reviews*. 2nd ed. Philadelphia: Saunders, 1988: 109.
70. Gouw ASH, Huitema S, Grond J et al. MHC antigen expression in human liver grafts: its role in rejection. *American Journal of Pathology* 1988; 133: 82-94.

7. Bibliografia

71. Riordan SM, Williams R. Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn? *Journal of Hepatology* 1999; 31: 1106-1119.
72. Meyer D, Löffeler S, Otto C, Czub S, Gassel H-J, Timmermann W, Thiede A, Ulrichs K. Donor-derived alloantigen-presenting cells persist in the liver allograft during tolerance induction. *Transplant International* 2000; 13:12-20.
73. Lu L, Mc Caslin D, Starzl TE, Thomson AW. Bone-Marrow derived dendritic cell progenitors (NLDC 145 pos., MHCII pos., B7-1dim, B7-2neg.) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. *Transplantation* 60: 1539-1545.
74. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic T-cell responses is mediated by CD40 signaling. *Nature* 1998; 393: 478-480.
75. Starzl te et al. The lost chord: microchimerism and allograft survival. *Immunology Today* 1996; 17: 577-584.
76. Bemelman F, Honey K, Adams E, Cobbold SP, Waldmann H. Bone Marrow Transplantation induces either clonal deletion or infectious disease tolerance depending on the dose. *Journal of Immunology* 1998; 160: 2645-2648.
77. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression can operate through indirect recognition. *Journal of Immunology* 1998; 161: 5813-5816.
78. Ko S, Deiwick A, Jager MD, Dinkel A, Rohde F, Fischer R, Tsui TY, Rittmann KL, Wonigeit K, Schlitt HJ. The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat. *Nature Medicine* 1999; 5: 1292-1297.
79. Waldmann H. Transplantation tolerance – where do we stand? *Nature Medicine* 1999; 5: 1245-1248.
80. Alters SE, Shizuru JA, Ackerman J, Grossman D, Seydel KB, Fathman CG. Anti CD4 mediates clonal anergy during transplantation tolerance. *Journal of Experimental Medicine* 1991; 173: 491.
81. Lehmann M, Kupiec-Weglinski JW, Risch K, Hancock WW, Muller A, Kuttler B, Hahn HJ, Brock JW, Volk HD. Anti-CD4 monoclonal antibody induced allograft tolerance in rats despite persistence of donor reactive T cells. *Transplantation* 1997; 64: 1181.
82. Mourad GJ, Preffer FI, Wee SL, Powelson JA, Kawai T, Delmonico FL, Knowles RW, Cosimi AB, Colvin RB. Humanized IgG1 and IgG4 anti CD4 monoclonal antibodies-effects on lymphocytes in the blood lymph nodes and renal allografts in cynomolgus monkeys. *Transplantation* 1998; 65:632.
83. Hamawy MM, Knechtle SJ. Strategies for tolerance induction in nonhuman primates. *Current Opinion of Immunology* 1998; 10: 513.

84. Krieger NR, Yuh D, McIntyre B, Flavin TF, Yin DO, Robbins R, Fathman CG. Prolongation of cardiac graft survival with anti-CD4 Ig plus hCTLA4 in primates. *Journal of Surgical Research* 1998; 76: 174-178.
85. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. *Science* 1992; 255: 1125.
86. Iwata T, Kamey Y, Esaki S, Takada T, Torii S, Yamashita A, Tomida S, Tamatani T, Miyasaka M, Yoshikai Y. Immunosuppression by anti-ICAM-1 and anti-LFA-1 monoclonal antibodies of free and vascularized skin allograft rejection. *Immunobiology* 1996; 195: 160.
87. Chan AC, Desai DM, Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. *Annual Reviews of Immunology* 1994; 12: 555.
88. Rollins SA, Kennedy SP, Chodera AJ, Elliot EA, Zavoico GB, Matis LA. Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2. *Transplantation* 1994; 57: 1709.
89. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM. Porcine aortic endothelial cells active human T cells: direct presentation of MHC antigens and costimulation by porcine ligands for LFA-1 and CD2 and CD28. *Immunity* 1994; 1:57.
90. Yamada K, Seebach JD, DerSimonian H, Sachs DH. Human anti-pig T cell-mediated cytotoxicity. *Xenotransplantation* 1996; 3:179.
91. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response: evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. *Journal of Immunology* 1995; 155: 5249.
92. Lakkis FG. Role of cytokines in transplantation tolerance: lessons learned from gene-knockout mice. *Journal of American Society of Nephrology* 1998; 8:1.
93. Neville DM, Scharff J, Hu HZ, Rigaut K, Shiloach J, Slingerland W, Jonger M. A new reagent for the induction of T cell depletion, anti-CD3-CRM-9. *Journal of Immunotherapy* 1996; 19:85.
94. Knechtle SJ, Vargo DJ, Fechner J, Zhai Y, Wang J, Hanaway MJ, Scharff J, Hu H, Knapp L, Watkins D, Necille DM. FN18-CRM19 immunotoxin promotes tolerance in primate renal allografts. *Transplantation* 1997; 63:1
95. Waldmann H. Transplantation tolerance-where do we stand? *Nature Medicine* 1999; 5: 1245.

96. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. *Science* 1996; 273: 109.
97. Schroeder RA, Marroquin CE, Kuo PC, MBA. Tolerance and the "Holy Grail" of transplantation. *Journal of Surgical Research* 2003; 111: 109-119.
98. Kawai T, Sachs DH, Cosimi AB. Tolerance to vascularized organ allograft in the large animal models. *Current Opinion of Immunology* 1999; 11: 516
99. Bishop GA, McCaughan GW, Sun J, Sheil AG. Microchimerism and transplant tolerance. *Immunology Today* 1997; 18:455
100. Cuturi MC, Josien R, Douillard P, Pannetier C, Cantarovich D, Smit H, Menoret S, Pouletty P, Clayberger C, Souillou. Prolongation of allogeneic heart graft survival in rats by administration of a peptide from the alpha 1 helix of the first domain of HLA-B7-01. *Transplantation* 1995; 59: 661.
101. Rossini AA, Greiner DL, Mordes JP. Induction of immunologic tolerance for transplantation. *Physiological Reviews* 1999; 79:99.
102. Konieczny BT, Dai Z, Elwood ET, Saleem S, Linsley PS, Baddoura FK, Larsen CP, Pearson TC, Lakkis FG. INF- γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T-cell costimulation pathways. *Journal of Immunology* 1998; 160: 2059-2064.
103. Furtado GC, deLafaille MAC, Kutchukhidze N, Lafaille JJ. Interleukine -2 signaling is required for CD4⁺ regulatory T cell function. *Journal of Experimental Medicine* 2002; 196: 851-857.
104. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K. Weaning of immunosuppression in living donor liver transplant recipients. *Transplantation* 2001; 72:449-454.
105. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism and allograft survival. *Immunology Today* 1996; 17:577.
106. Dalmaso A, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. *Transplantation* 1991; 52: 530-533.
107. Lawson JH, Daniels LJ, Platt JL. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. *Transplantation Proceedings* 1997, 29:884-885
108. Pareti FI, Mazzucoto M, Bottiri E, Marrucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. *British Journal of Haematology* 1992; 82: 81-86.

-
109. Hammer C. Xenotransplantation: The good, the bad, and the ugly or how far are we to clinical application? *Transplantation Proceedings* 2003; 35: 1256-1257.
110. Mollevi DG, Jaurieta E, Ribas Y, Hurtado I, Serrano T, Gomez N, de Oca J, Fiol C, Figueras J. Liver xenotransplantation: changes in lipid and lipoprotein concentration after long-term graft survival. *Journal of Hepatology* 2000; 32:655-60.
111. Specke V, Rubant S, Denner J. Productive infection of human primary cells and cell lines with porcine endogenous retroviruses. *Virology* 2001; 285: 177-180
112. Paradis K, Langford G, Long Z et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. *Science* 1999; 285: 1236-1241
113. Patience C, Greenstein J. PERV clarification. *Nature Biotechnology* 2001;19: 508
114. Daar AS. Xenotransplantation: recent scientific developments and continuing ethical discourse. *Transplantation Proceedings* 2003; 35: 2821-2822.
115. Desmet VJ. Introduction: organizational principles in *The liver: biology and pathobiology*. Third edition. Edited by Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. 3ª edición. Ed Raven Press Ltd, New York 1994.
116. Alberts B, Bray D, Lewis J, Rall M, Roberts K, Watson JD. *Molecular biology of the cell*. 3ª ed. Garland Publishing Inc. 1994 New York.
117. Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. *The liver: biology and pathobiology*, 3ª edición. Ed. Raven Press Ltd, 1994 New York.
118. Cuevas-Mons V, Castillo-Olivares JL. *Introducción al trasplante de órganos y tejidos*. 2ª Ed Aran Ediciones 1999 Madrid.
119. Grewel HP, Thistlewaite JR, Loss GE, Fisher JS, Cronin DC, Siegel CT, et al. Complications in 100 living donors. *Annals of Surgery* 1998; 228: 214-19.
120. Gunsalus JR, Brady DA, Coulter SM, et al. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. *Nature Medicine* 1997; 3:48-53.
121. Grobstein C. Inductive epithelio-mesenchymal interaction interaction in cultured organ rudiments of the mouse. *Science* 1953; 118: 52-55.
122. Ekblom P. Formation of basement membranes in the embryonic kidney: an immunohistological study. *Journal of Cell Biology* 1981; 91: 1-10
123. Hammerman MR. Growing kidneys. *Current Opinion in Nephrology and Hypertension* 2001; 10: 13-17.

124. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Starzl TE. Liver transplantation across ABO blood groups. *Surgery* 1986; 100: 342-348.
125. Demetris AJ, Nakamura K, Yagihashi A et al. A clinicopathological study of human liver allograft recipients harbouring preformed IgG lymphocytotoxic antibodies. *Hepatology* 1992; 3: 671-681.
126. Gugenheim J, Amorosa L, Gigou M, Fabiani B, Rouger P, Gane P, Reynes M, Bismuth H. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. *Transplantation* 1990; 144: 309-313
127. Knechtle SJ, Yamaguchi Y, Coundouriotis A, Bollinger RR. Mediation of hyperacute rejection of rat hepatic allografts by RT-1 antigens. *Transplantation* 1989; 48: 723-725.
128. Baldwin WM III, Paul LC, Claas FH, Daha MR. Destructive and protective effects of antibody on transplants in humans: practical and theoretical considerations. *Progress in Clinical and Biological Research* 1986; 224: 41-67.
129. Lee S, Edgington TS. Heterotopic liver transplantation using inbred rat strains. *American Journal of Pathology* 1966; 52: 649.
130. Korto WJ, Wolff ED, Eastham WN. Heterotopic auxiliary liver transplantation in rats. *Transplantation* 1971; 12: 1971.
131. Hess F, Jerusalem C, van der Heyde NM. Advantages of auxiliary liver homotransplantation in rats. *Archives of Surgery*. 1972; 104: 76.
132. Lee S, Charter AC, Orloff MJ. Simplified technique for orthotopic liver transplantation in the rat. *American Journal of Surgery* 1975; 130: 38.
133. Zimmermann FA, Butcher GW, Davies H ff S, Brons G, Kamada N, Turel O. Techniques for orthotopic liver transplantation in the rat and some studies of the immunologic responses to fully allogeneic liver grafts. *Transplantation Proceedings* 1979; 11: 571.
134. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. *Transplantation* 1979; 28:47-50.
135. Ulrichs K, Engemann R, Thiede A, Müller-Ruchholtz W. Allograft tolerance in rats with orthotopic liver transplants: advantages of rearterialization. *European Surgical Research* 1981; 13:79
136. Ramos E, Sanfey H, Fernandez-Cruz L. Arterialization of orthotopic liver transplants in rats by a sleeve anastomosis technique. *Transplantation Proceedings* 1992; 24: 150-152.
137. Ye Y, Luo Y, Kobayashi T, Taniguchi S, Li S, Niekrasz M, Kosanke S, Baker J, Miele L, Smith D, Cooper DKC. Secondary organ allografting after a primary "bridging" xenotransplant. *Transplantation* 1995; 60: 19-22.

-
138. Chice L, Bittard H, Adam R, Castaing D, Bismuth H. Xenogeneic liver transplantation: its influence on secondary allogeneic graft rejection. *Transplantation Proceedings* 1990; 22: 2333.
139. Gannedahl G, Tufveson G. The impact of xenograft rejection on future grafting. *Transplantation Proceedings* 1992; 24: 276.
140. Makowka L, Cramer DV, Hoffman A, Breda M, Sher L, Eiras-Hreha G, et al. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. *Transplantation* 1995; 59: 1654-1659.
141. Levy M, Crippin J, Sutton S, Netto G, McCormack J, Curiel T, Goldstein RM, Newman J, Gonwa TA, Banchereau J, Diamond LE, Byrne G, Logan J, Klintmalm G. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the Porcine Endogenous Retrovirus. *Transplantation* 2000; 69: 272
142. Murase N, Starzl T, Demetris AJ, Valdivia L, Tanabe M, Cramer D, Makowka L. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. *Transplantation* 1993; 55: 701-708.
143. Sankary HN, Yin D-P, Chong ASF, Ma L-L, Blinder L, Shen JK, Foster P, Williams JW. FK506 treatment in combination with Leflunomide in hamster-to-rat heart and liver xenograft transplantation. *Transplantation* 1998; 66: 832-837.
144. Chong ASF, Ma L-L, Shen J, Blinder L, Yin D-P, Williams JW. Modification of humoral responses by the combination of leflunomide and cyclosporine in Lewis rats transplanted with hamster hearts. *Transplantation* 1997; 64: 1650-1657.
145. Xiao F, Chong AS, Foster P, Sankary H, McChesney L, Koukoulis G, Yang J, Frieders D, Williams JW. Leflunomide controls rejection in hamster to rat cardiac xenografts. *Transplantation* 1994; 58: 828-834.
146. Lin Y, Goebels J, Xia G, Ji P, Vandeputte M, Waer M. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. *Nature Medicine* 1998; 4: 173-180.
147. Yin D, Ma LL, Blinder L, Shen J, Sankary H, Williams JW, Chong ASF. Induction of species-specific host accommodation in the hamster-to-rat xenotransplantation model. *Journal of Immunology* 1998; 161:2044-2051.
148. Lin Y, Vandeputte M, Waer M. Contribution of activated macrophages to the process of delayed xenograft rejection. *Transplantation* 1997; 64: 1677-1683.

149. Brouard S, Bouhours D, Sébille F, Ménoret S, Soullou JP, Vanhove B. Induction of anti-Forsman antibodies in the hamster-to-rat xenotransplantation model. *Transplantation* 2000; 69: 1193-1201.
150. Chong ASF, Shen J, Xiao F, Blinder L, Wei L, Sankary H, Foster P, Williams J. Delayed xenograft rejection in the concordant hamster heart into Lewis rat model. *Transplantation* 1996; 62: 90-96.
151. Monden M, Valdivia LA, Gotoh M et al. Hamster-to-rat liver xenografts. *Transplantation* 1998; 43: 745-746.
152. Valdivia LA, Monden M, Gotoh M, Hasuike Y, Kubota N, Ichikawa T, Okamura J, Mori T. Prolonged survival of hamster-to-rat liver xenografts using splenectomy and cyclosporine administration. *Transplantation* 1987; 44: 759-763.
153. Valdivia LA, Fung JJ, Demetris AJ, Starzl TE. Differential survival of hamster-to-rat liver and cardiac xenografts under FK506 immunosuppression. *Transplantation Proceedings* 1991; 23: 3269-3271.
154. Murase N, Starzl TE, Demetris AJ, Valdivia L, Tanabe M, Cramer D, Makowka L. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. *Transplantation* 1993; 55: 701-708.
155. Langer A, Valdivia LA, Murase N, Woo J, Celli S, Fung JJ, Starzl TE, Demetris AJ. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. *American Journal of Pathology* 1993; 143: 85-98.
156. Valdivia LA, Demetris AJ, Fung JJ, Celli S, Murase N, Starzl TE. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. *Transplantation* 1993; 55: 659-661.
157. Valdivia LA, Demetris AJ, Fung JJ, Celli S, Frye C, Murase N, Starzl TE. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. *Transplantation Proceedings* 1993; 25: 414-415.
158. Valdivia LA, Fung JJ, Demetris AJ, Celli S, Pan F, Tsugita M, Starzl TE. Donor species complement after liver xenotransplantation. *Transplantation* 1994; 57: 918-922.
159. Celli S, Valdivia LA, Kelly RH, Demetris AJ, Fung JJ, Rao AS, Pan F, Tsugita M, Starzl TE. Functional cooperation of xenoproteins after hamster-to-rat rat liver transplantation: with particular reference to hamster C3 and secretory component for rat IgA. *Xenotransplantation* 1995; 2: 46-51.
160. Celli S, Valdivia LA, Fung JJ, Kelly RH. Early recipient-donor switch of the complement type after liver xenotransplantation. *Immunology Investigations* 1997; 26: 589-600.

-
161. Celli S, Valdivia LA, Fung JJ, Kelly RH, Pan F, Tsugita M, Demetris AJ, Starzl TE. Metabolic changes in the recipient after successful liver xenotransplantation in the rat. *Transplantation Proceedings* 1994; 26: 1207.
162. Valdivia LA, Lewis JH, Celli S, Bontempo FA, Fung JJ, Demetris AJ, Starzl TE. Hamster coagulation and serum proteins in rat recipients of hamster xenografts. *Transplantation* 1993; 56: 489-490.
163. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating-factor: a mediator for clinicians. *Journal of International Medicine* 1995; 238: 5-20.
164. Evans RD, Lud P, Williamson DH. Platelet-activating factor and its metabolic effects. *Prostaglandins Leukotrienes Essential Fatty Acids* 1991; 44: 1-10.
165. Benveniste J, Heson PM, Cochrane C. Leukocyte-dependent histamine release from rabbit platelets. *Journal of Experimental Medicine* 1972; 136: 1356-1375.
166. Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, tetta C. Release of platelet-activating factor (PAF) and histamine. *Immunology* 1981; 42: 191-199.
167. Feuerstein G, Boyd LM, Erza D, Goldstein RE. Effect of platelet activating factor on coronary circulation of the domestic pig. *American Journal of Physiology* 1984; 246: H466-H471.
168. Humphrey DM, McManus LM, Satouchi K, Hanahan DJ, Pinckard RN. Vasoactive properties of acetyl glyceril ether phosphorylcholine and analogues. *Laboratory Investigation* 1982; 46: 422-427.
169. Kenzora JL, Perez JE, Bergmann SR, Lange LG. Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload and contractility in dogs. *Journal of Clinical Investigations* 1984; 74: 1193-1203.
170. Mayatepek E, Hoffmann GF. Leukotrienes: biosynthesis, metabolism and pathophysiologic significance. *Pediatric Research* 1995; 37: 1-9.
171. Handley DA, Lee ML, Saunders RN. Evidence for a direct effect on vascular permeability of platelet-activating factor-induced hemoconcentration in the guinea-pig. *Thrombosis and Haemostasis* 1985; 54: 756-759.
172. Snyder F. Platelet-activating factor, related alkyl glycerolipids, and their precursors. En *Platelet-activating Factor and related lipid mediators*. F L Snyder, editor. Plenum Publishing Corp, New York, 1987; 89-114.
173. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. *American Journal of Physiology* 1990; 259: C697-C708.

174. Koyama I, Bulkey GB, Williams GM, Im MJ. The role of oxygen free radicals in mediating the reperfusion injury of cold -preserved ischemic kidney Transplantation 1985; 40: 590.
175. Blank ML, Spector AA, Kaduce TL, Lee T, Snyder F. Metabolism of platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-alkyl-2-acetyl-sn-glycerol by human endothelial cells. *Biochimica et Biophysica Acta* 1986; 876: 373-378.
176. Bussolino F, Brevario F, Aglietta M, Sanavio F, Bosia A, Dejana E. Studies of the mechanism of interleukin 1 stimulation of platelet-activating factor synthesis in human endothelial cells in culture. *Biochimica et Biophysica Acta* 1987; 927: 43-54.
177. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated Platelet-activating Factor: a novel mechanism for signaling intercellular adhesion. *Journal of Cell Biology* 1990; 110: 529-540.
178. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. *Journal of Biology and Chemistry* 1987; 262: 4223-4230.
179. Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase activity in human tissue and blood cells. *Lipids* 1991; 26: 979-985.
180. Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G, Condorelli M, Chiariello M, Triggiani M. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. *Journal of Clinical Investigations* 1994; 93: 2408-2416.
181. Ye RD, Prossnitz ER, Zou AH, Cochrane CG. Characterization of a human cDNA that encodes a functional receptor for platelet-activating factor. *Biochemical and Biophysical Research Communications* 1991; 180: 105-111.
182. Müller E, Dagenais P, Alami N, Rola-Pleszczynski M. Identification and functional characterization of platelet-activating factor receptors in human leukocytes populations using polyclonal anti-peptide antibody. *Proceedings of National Academy of Science USA* 1993; 90: 5818-8522.
183. Oullet S, Müller E, Rola-Pleszczynski M. INF- γ upregulates platelet-activating factor receptor gene expression in human monocytes. *Journal of Immunology* 1994; 152: 5092-5099.
184. Thivierge M, Alami N, Müller E, de Brum-Fernandez AJ, Rola-Pleszczynski M. Transcriptional modulation of platelet-activating factor receptor gene expression by cyclic AMP. *Journal of Biology and Chemistry* 1993; 268: 1757-17462.

185. Braquet P, Paubert-Braquet M, Bourgain R, Bussolino F, Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. *Journal of Lipid Mediators* 1989; 1: 75.
186. Klopogge E, De Haas GM, Gorter G, Akkerman JWN. Properties of PAF-acether induced platelet aggregation and secretion. *Studies in gel filtered human platelets. Thrombosis Research* 1983; 29: 595.
187. Klopogge E, Akkerman JWN. Binding and kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets. *Biochemical Journal* 1984; 223: 901.
188. Fauler J, Sielhorst G, Frölich JC. Platelet activating factor induces the production of leukotrienes by human monocytes. *Biochimica et Biophysica Acta* 1989; 1013: 80.
189. Pignol B, Henane S, Mencia-Huerta JM, Rola-Pleszczynski M, Braquet P. Effect of PAF-acether (platelet-activating factor) and its specific antagonist, BN-52021, on interleukin 1 (IL-1) synthesis and release by rat monocytes. *Prostaglandins* 1987; 33: 931.
190. Bonavida B, Mencia-Huerta JM, Braquet P. Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion. *Journal of Lipid Mediators* 1990; 2: S65.
191. Camussi G, Aglietta M, Malavas F, Tetta C, Piacibello W, Sanavio F, Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. *Journal of Immunology* 1983; 131: 2397.
192. Bussolino F, Camussi G, Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin-1 α . *Journal of Biological Chemistry* 1988; 263: 11856.
193. Bussolino F, Camussi G, Breviario F, Bertocchi F, Ghigo D, Pescarmona GP, Aglietta M, Garbarino G, Bosia A, Dejana E. Endothelial cells and inflammation platelet activating factor, interleukin 1, Tumor Necrosis Factor, and Circulating Neutrophils. En *Platelet-activating Factor and Cell Immunology*. Braquet P. ed. *New Trends Lipid Mediators Res. Basel Karger* 1988; Vol. 1: 135.
194. Braquet P, Touqui T, Shen Y, Vargaffig BB. Perspectives in Platelet-activating factor research. *Pharmacological Reviews* 1987; Vol. 39. No. 2: 97.
195. Humphrey DM, Hanahan DJ, Pinckard RN. Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine. *Laboratory Investigation* 1982; 47: 227.
196. Ito O, Camussi G, Milgrom F, Andres G. Hyperacute renal allograft rejection in the rabbit: the role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. *Laboratory Investigation* 51: 148. 1984.

197. Pignol B, Henane S, Mencia-Huerta JM, Braquet P. Effect of long-term treatment with platelet-activating factor on cytokine production by rat spleen cells. *International Archives of Allergy & Applied Immunology* 1989; 88:161-163.
198. Mc Ever R. Leukocyte-endothelial cell interactions. *Current Opinion in Cell Biology* 1992; 4: 840-849.
199. Furie MB, Mc Hugh DD. Migration of neutrophils across endothelial monolayers with interleukin-1 or tumor necrosis factor- α . *Journal of Immunology* 1989; 143: 3309-3317.
200. Walcher F, Marzi I, Fischer R, Bauer M, Larsen R. Platelet-activating factor is involved in the regulation of pathological leukocyte adhesion after liver transplantation. *Journal of Surgical Research* 1996; 61:244-249.
201. Lorant DE, Topham MK, Whatley RE, Mc Ever RP, McIntyre TM, Prescott SM, Zimmermann GA. Inflammatory roles of p-selectin. *Journal of Clinical Investigations* 1993; 92: 559-570.
202. Milhoan KA, Lane TA, Bloor CM. Hypoxia induces endothelial cells to increase their adherence for neutrophils: role of PAF. *American Journal of Physiology* 1992; 263: H956-962.
203. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature* 1962 ; 194 : 927-929.
204. Carceller E, Merlos M, Giral M, Balsa D, Gargia Rafanell J, Forn J. Design, synthesis and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazol [4,5c]pyridine derivatives as potent, orally active platelet-activating factor antagonist. *Journal of Medicine and Chemistry* 1996 ; 39 : 487-493.
205. Schwartz JD, Shamamian P, Grossi EA, Schwartz DS, Marcus SG, Steiner F, Jacobs CE, Tayyarah M, Eng K, Colvin SB, Galloway AC. Lexipafant inhibits platelet-activating factor enhanced neutrophil functions. *Journal of Surgical Research* 1997; 69: 240-248.
206. Franciose RJ, Moore EE, Moore FA, Read RA, Carl VS, Banerjee A. Hypoxia/reoxygenation of human endothelium activates PMNs to detach endothelial cells via a PAF mechanism. *Journal of Surgical Research* 1996; 61: 459-462.
207. Tamm M, Bihl M, Eckelberg O, Stulz P, Perruchoud AP, Roth M. Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells. *American Journal of Respiratory Cell and Molecular Biology* 1998; 19: 653-661.
208. Koyama S, Sato E, Nomura H, Kuto K, Miura M, Yamashita T, Nagai S, Izumi T. Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. *American Journal of Pathology* 1998; 153: 1885-1893.

209. Li S, Meng Q, Zhang L. Experimental therapy of a platelet-activating factor antagonist (ginkgolide B) on photochemically induced thrombotic cerebral ischaemia in tree shrews. *Clinical Experimental Pharmacology and Physiology* 1999; 26: 824-825.
210. Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Walchers T. Impact of PAF antagonist BN 52021 (Ginkgolide B) on post-ischemic graft function in clinical lung transplantation. *Journal of Heart and Lung Transplantation* 2001; 20: 358-363.
211. Sun Z, Wang X, Lasson A, Bojesson A, Annborn M, Anderson R. Effects of inhibition of PAF, ICAM-1 and PECAM-1 on gut barrier failure caused by intestinal ischemia and reperfusion. *Scandinavian Journal of Gastroenterology* 2001; 20: 358-363.
212. Schroder E, Pouleur H, VanMechelen W, Keyeux A, Raigoso J, Charlier A: Alterations in endocardial vascular resistance after reperfusion in a low flow, high demand model of ischemia: effects of dipyridamole and WEB-2086, a platelet factor antagonist. *Journal of American College of Cardiology* 1990; 16: 1750-1759.
213. Torras J, Cruzado JM, Riera M, Condom E, Duque N, Herrero I, Merlos M, Espinosa L, Lloberas N, Egido J, Grinyó JM. Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. *Kidney International* 1999; 56: 1798-1808.
214. Minor T, Isselhard W, Yamaguchi T. Involvement of platelet activating factor in microcirculatory disturbances after global hepatic ischemia. *Journal of Surgical Research* 1995; 58: 536-540.
215. Tohda Y, Muraki M, Kubo H, Itoh M, Haraguchi R, Nakajima S, Fukuoka M. Role of chemical mediators in airway hyperresponsiveness in an asthmatic model. *Respiration* 2001; 68: 73-77.
216. Lane JS, Todd KE, Gloor B, Chandler CF, Kau AW, Ashley SW, Reber HA, McFadden DW. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis. *Journal of Surgical Research* 2001; 99: 365-370.
217. Carceller E, Salas J, Merlos M, Giral M, Ferrando R, Escamilla I, Ramis J, Garcia-Rafanell J, Forn J. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. *Journal of Medicine and Chemistry* 2001; 44: 3001-3013.
218. Makowka L, Chapman FA, Cramer DV, Qian SG, Sun H, Starzl TE. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts. *Transplantation* 1990; 50: 359-365.

219. O'Hair DP, Roza AM, Pieper GM, Komorowski R, Moore G, McManus RP, et al. Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. *Transplantation Proceedings* 1992; 24:702-703.
220. O'Hair DP, Roza AM, Komorowski R, Moore G, McManus RP, Johnson CP et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. *Journal of Lipid Mediators* 1993; 7:79-84.
221. Saumweber DM, Bergmann R, Gokel M, Brecht HM, Hammer C. The involvement of Platelet-activating factor in hyperacute xenogeneic rejection and its modulation by the PAF-antagonist WEB 2086BS. *Transplantation Proceedings* 1991; 23:576-578.
222. Cruzado JM, Torras J, Riera M, Lloberas N, Herrero I, Condom E, et al. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model. *Clinical Experimental Immunology* 1998; 113:136-144.
223. Lloberas N, Cruzado JM, Torras J, Herrero-Fresneda I, Riera M, Merlos M, Grinyo JM. Protective effect of UR-12670 on chronic nephropathy induced by warm ischaemia in ageing uninephrectomized rats. *Nephrology Dialysis Transplantation* 2001; 16:735-41.
224. Torras J, Cruzado JM, Riera M, Condom E, Duque N, Herrero I, Merlos M, Espinosa L, Lloberas N, Egido J, Grinyo JM. Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. *Kidney International* 1999; 56:1798-808.
225. Lee S, Charters AC, Chandler JG, Orloff MJ. A technique for orthotopic liver transplantation in the rat. *Transplantation* 1973; 16: 664.
226. Miyanari N, Yamaguchi Y, Matsuno K, Tominaga A, Goto M, Ichiguchi O, Mori K, Ogawa M. Persistent infiltration of CD45RC⁻ CD4⁺ cells, Th2-like effector cells, in prolonging hepatic allografts in rats pretreated with a donor-specific blood transfusion. *Hepatology* 1997; 25: 1008-13.
227. Brouard S, Vanhove B, Gagne K, Neumann A, Douillard P, Moreau A, Cuturi C, Souillou JP. T Cell repertoire alterations of vascularized xenografts. *Journal of Immunology* 1999; 162: 3367.
228. Davenport M, Peakman M, Dunne JB, Gonde CE, Vergani D, Williams R, Tredger JM. Peripheral blood and intrahepatic subsets of T lymphocyte activation and function in liver allograft rejection and drug-induced tolerance in rats. *Transplant Immunology* 1996; 4: 126-132.
229. Kamada N. The process of rejection and nonrejection-Histology and functional competence of rat livers after transplantation. In: Kamada N, editor. *Experimental liver transplantation*. Boca Raton RC Press, 1988:7-18.

-
230. Zhao D, Zimmermann A, Kuznetsova LV, Wheatley AM. Regression of bile duct damage and bile duct proliferation in the non-rearterialized transplanted rat liver is associated with spontaneous graft rearterialization. *Hepatology* 1995; 21:1353-60
231. Sun J, McCaughan GW, Matsumoto Y, Sheil AGR, Gallagher ND, Bishop GA. Tolerance to rat liver allografts. I.-Differences between tolerance and rejection are more marked in the B cell compared with the T cell or cytokine response. *Transplantation* 1994; 57: 1349-57
232. Langer A, Valdivia LA, Murase N, Woo J, Celli S, Fung JJ, Starzl TE, Demetris AJ. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. *American Journal of Pathology* 1993; 143:85-98.
233. Huang WH, Y Yan, BD Boer, GA Bishop and AK House. A short course of Cyclosporin immunosuppression inhibits rejection but not tolerance of rat liver allografts. *Transplantation* 2003; 75: 368-74.
234. Thomas ML. The leukocyte-common antigen family. *Annu Rev Immunol* 1989; 7: 339-369.
235. Ramírez F, Mason D. Recirculatory and Sessile CD4⁺ T lymphocytes differ on CD45RC expression. *Journal of Immunology* 2000; 165: 1816-1823.
236. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV.Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *Journal of Experimental Medicine* 1989; 170: 2081-95.
237. Papp I, Wieder KJ, Sablinski T, O'Connell PJ, Milford EL, Stom TB, Kupiec-Weglinski JW. Evidence for functional heterogeneity of rat CD4⁺ T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. *Journal of Immunology* 1992; 148: 1308-1314.
238. MCKnight A, Barclay A, Mason D. Molecular cloning of rat interleukin 4 cDNA and analysis of cytokine repertoire of subsets of CD4⁺ T cells. *European Journal of Immunology* 1991; 21: 1187-
239. Yang C, Bell E. Functional maturation of recent thymic emigrants in the periphery: development of alloreactivity correlates with the cyclic expression of CD45RC isoforms. *European Journal of Immunology* 1992; 22:2261-9.
240. Ramirez P, Chavez R, Majado M, Munitiz V, Munoz A, Hernandez Q et al. Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days. *Transplantation* 2000; 70:989-998.
241. Esmon CT. Role of coagulation inhibitors in inflammation. *Thrombosis and Haemostasis* 2001; 86:51-6.

242. Jamison CS, McDowell SA, Marlar RA, Degen SJ. Developmental expression of protein C and protein S in the rat. *Thrombosis Research*. 1995; 78(5):407-19.
243. Daly ME, Beauchamp NJ. Inherited protein S deficiency: from genotip to phenotip. *Haematologica* 2003; 88: 363-7.
244. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. *Lancet* 1992; 339:1579-1582.
245. Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA et al. Systemic chimerism in human female recipients of male livers. *Lancet* 1992; 340:876-877.
246. Takada Y, Boudjema K, Jaeck D. Effects of platelet-activating factor antagonist on preservation reperfusion injury of the graft in porcine orthotopic liver transplantation. *Transplantation* 1995; 59:10-16.
247. Pignol B, Henane S, Mencia-Huerta JM, Braquet P. Effect of long-term treatment with platelet-activating factor on cytokine production by rat spleen cells. *International Archieve of Allergy and Applied Immunology* 1989; 88:161-163.
248. Patke CL, Green CG, Shearer WT. Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B-cells. *Clinical Diagnosis in Laboratory Immunology* 1994; 1:424-432.
249. Boes M. Role of natural immune IgM antibodies in immune responses. *Molecular Immunology* 2000; 37: 1141-1149.